Summary
- Profile Type
- Technology offer
- POD Reference
- TOHU20250203020
- Term of Validity
- 3 February 2025 - 3 February 2026
- Company's Country
- Hungary
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Hungary-based CRO specializing in in vivo preclinical studies offers high-quality, ethical animal models for drug development, focusing on anticancer and other therapies. Targeting pharma, SMEs, and academia, the company provides tailored, cost-effective solutions. Seeking collaborations within EU consortiums as partner or associated roles to accelerate R&D and innovation.
- Full Description
-
A biotechnology research and contract research organization (CRO) based in Hungary specializes in in vivo preclinical studies to support the development of new drugs and therapies. Animal model-based research is crucial for evaluating the efficacy and safety of potential drug candidates before they progress to clinical trials. However, traditional models often fail to fully replicate human disease conditions, creating a need for customized, well-characterized models that enhance translational research.
One of the key challenges in drug development is ensuring that a new compound is both effective and safe for human use. While in vitro models provide valuable early-stage insights, they are insufficient for predicting a drug’s effects in a complex biological system. As a result, in vivo preclinical studies remain essential in the drug discovery pipeline. Many existing standard animal models lack disease-specific modifications, limiting their ability to generate clinically relevant data. This has led to increasing demand for advanced models that accurately reflect real-world disease mechanisms, particularly in fields such as oncology, metabolic disorders, and neurodegenerative diseases.
To address these challenges, the Hungarian SME develops tailored animal models designed to assess drug safety, efficacy, and mechanisms of action. These models adhere to international ethical standards, including the 3Rs principle (Replacement, Reduction, Refinement), ensuring high-quality, responsible research.
The SME seeks international partnerships in participation in EU-funded consortia – engaging in Horizon Europe and other funding programs to drive multidisciplinary innovation in drug research. The collaboration framework is structured to meet the specific needs of each partner – pharmaceutical companies, SMEs, universities. By fostering these strategic partnerships, the SME contributes to global medical innovation while maintaining high ethical standards in preclinical research. These efforts not only support scientific discovery but also improve healthcare outcomes by ensuring that promising drug candidates advance efficiently and successfully toward clinical application. - Advantages and Innovations
-
The tailored animal models developed by the SME offer improved translational accuracy compared to standard preclinical models, providing a more precise representation of human disease mechanisms. This leads to more reliable assessments of drug efficacy and safety, reducing the risk of failure in later clinical stages. The technology adheres to the 3Rs principle, ensuring ethical and regulatory compliance while minimizing animal use and maintaining high data quality. Its applications extend across oncology, metabolic disorders, and neurodegenerative diseases, with additional potential in toxicology and immunology studies.
The models are designed to be cost-effective and efficient, optimizing study designs to reduce unnecessary testing, lower development costs, and shorten preclinical timelines. Their scalability and customizability allow for adaptation to specific disease conditions and drug mechanisms, ensuring seamless integration into diverse research pipelines. Beyond pharmaceuticals, this approach has potential applications in biotechnology, regenerative medicine, and biomarker discovery, supporting broader innovation in therapeutic development. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
The SME is seeking EU consortium members, consortium coordinators, and other organizations to collaborate on Horizon Europe and other EU-funded research projects focused on preclinical drug development and translational medicine. The ideal partners include pharmaceutical companies, biotechnology firms, academic and research institutions, hospitals, clinical research centers, and regulatory bodies involved in drug discovery, preclinical testing, and translational research.
Potential partners should specialize in preclinical and translational research, regulatory compliance, biomarker identification, drug efficacy studies, and advanced therapeutic strategies. Institutions with expertise in oncology, metabolic disorders, neurodegenerative diseases, toxicology, and drug delivery technologies are particularly relevant. As part of the collaboration, partners will engage in joint development of novel preclinical models, contributing to drug screening, validation, and efficacy assessments. Industrial partners and SMEs can participate by facilitating technology transfer, commercialization, and licensing of novel therapeutic candidates. By fostering these collaborations, the SME aims to accelerate drug development, enhance translational research, and contribute to the advancement of innovative therapies. This initiative ensures that preclinical results lead to clinically meaningful outcomes, ultimately improving patient care and therapeutic innovation in Europe. - Type and Size of Partner
- SME 11-49
- SME <=10
- University
- SME 50 - 249
- Big company
- R&D Institution
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001012 - Medical Research
- 06001015 - Pharmaceutical Products / Drugs
- 06002010 - Toxicology
- Market keywords
- 04012 - Toxicology
- 05003001 - Therapeutic services
- 05007002 - Pharmaceuticals/fine chemicals
- Sector Groups Involved
- Health
- Targeted countries
- All countries